Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,248,372,445.81, representing a year-on-year increase of 13.42%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 269,516,681.64, reflecting a significant increase of 63.84% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 265,681,678.26, up by 31.68% year-on-year[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.19, an increase of 58.33% compared to the previous year[4] - The weighted average return on equity increased by 1.01 percentage points to 2.79%[4] - Total operating revenue for Q1 2023 reached CNY 2,248,372,445.81, an increase of 13.4% compared to CNY 1,982,418,083.43 in Q1 2022[18] - Total operating costs for Q1 2023 were CNY 1,942,265,271.77, up from CNY 1,771,349,767.48 in Q1 2022, reflecting a year-over-year increase of 9.6%[19] - Net profit for Q1 2023 was CNY 272,609,567.16, compared to CNY 169,697,089.00 in Q1 2022, representing a growth of 60.6%[20] - Earnings per share for Q1 2023 were CNY 0.19, an increase from CNY 0.12 in Q1 2022[20] - The company reported a total comprehensive income of CNY 286,068,051.13 for Q1 2023, compared to CNY 165,454,901.35 in Q1 2022[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 16,283,942,244.29, a slight increase of 0.35% from the end of the previous year[5] - The equity attributable to shareholders increased by 2.96% to CNY 9,787,196,127.43 compared to the end of the previous year[5] - Total liabilities decreased from approximately 16.228 billion RMB at the end of 2022 to 16.284 billion RMB as of March 31, 2023[17] - The company's total liabilities amounted to CNY 6,351,886,547.94, a decrease from CNY 6,605,796,858.33 in the previous year[18] - The total equity attributable to shareholders reached CNY 9,787,196,127.43, up from CNY 9,505,536,761.16 year-over-year[18] - The total assets increased to ¥11,807,323,967.10 from ¥11,480,186,220.60, reflecting a growth of 2.8%[26] - The total liabilities rose to ¥5,214,583,701.41, up from ¥5,031,260,300.74, indicating a 3.6% increase[26] - The company's equity increased to ¥6,592,740,265.69, compared to ¥6,448,925,919.86, marking a growth of 2.2%[26] Cash Flow - The company reported a net cash flow from operating activities of CNY 246,430,917.01, with no year-on-year comparison available[4] - The net cash flow from operating activities for Q1 2023 was ¥246,430,917.01, a significant improvement compared to a net outflow of ¥319,720,493.05 in Q1 2022[22] - Total cash inflow from operating activities reached ¥2,550,337,848.75, up from ¥1,701,437,510.63 in the same period last year, indicating a growth of approximately 50%[22] - Cash outflow from operating activities was ¥2,303,906,931.74, compared to ¥2,021,158,003.68 in Q1 2022, reflecting an increase of about 14%[22] - The net cash flow from investing activities was ¥19,937,369.33, a decrease from ¥170,854,544.09 in Q1 2022[23] - Cash inflow from financing activities totaled ¥349,771,365.48, down from ¥1,513,759,201.90 in the previous year, representing a decline of approximately 77%[23] - The net cash flow from financing activities showed a negative balance of ¥91,114,391.87, compared to a negative ¥379,678,190.29 in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were ¥2,695,907,715.54, an increase from ¥2,128,006,127.97 at the end of Q1 2022[23] Operational Highlights - The company reported a total order backlog of 9.736 billion RMB as of Q1 2023, representing a year-over-year increase of 31.31%[14] - Domestic order backlog reached 5.851 billion RMB, up 17.55% year-over-year, while overseas order backlog was 3.885 billion RMB, showing a significant growth of 59.42%[14] - The company is focusing on expanding its market presence and enhancing its product offerings through new technologies and strategies[14] Expenses - The company’s management expenses increased by 45.86% primarily due to the merger of five rehabilitation hospitals and the establishment of new hospitals[10] - Research and development expenses for Q1 2023 totaled CNY 79,357,579.39, up from CNY 66,944,342.94 in Q1 2022, indicating a 18.5% increase[19] - Research and development expenses for Q1 2023 were ¥18,672,699.63, up from ¥14,999,438.49, reflecting a 24.0% increase year-over-year[27] - The company's financial expenses for Q1 2023 were CNY 1,061,995.80, compared to a gain of CNY 21,973,639.76 in Q1 2022[19]

证券代码：601567 证券简称：三星医疗 公告编号：临 2023-037 宁波三星医疗电气股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 09 日上午 10:00-11:30 宁波三星医疗电气股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 05 月 09 日上午 10:00-11:30 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ ...

Financial Performance - The company's operating revenue for 2021 was ¥7,022,902,468.70, a decrease of 0.98% compared to ¥7,092,708,995.09 in 2020[23]. - The net profit attributable to shareholders for 2021 was ¥690,042,564.52, representing a decline of 27.83% from ¥956,119,901.66 in 2020[23]. - The cash flow from operating activities decreased significantly by 83.83%, amounting to ¥198,943,484.74 in 2021 compared to ¥1,230,542,632.97 in 2020[23]. - The total assets at the end of 2021 were ¥14,865,322,029.25, an increase of 8.54% from ¥13,696,278,189.50 at the end of 2020[23]. - The basic earnings per share for 2021 was ¥0.50, down 27.83% from ¥0.69 in 2020[24]. - The weighted average return on equity for 2021 was 7.90%, a decrease of 3.43 percentage points from 11.33% in 2020[24]. - The net profit excluding non-recurring gains and losses was ¥519,178,466.27, down 25.86% from ¥700,275,830.88 in 2020[23]. - The company's net assets attributable to shareholders increased by 2.93% to ¥8,873,230,301.13 at the end of 2021 from ¥8,620,717,871.96 at the end of 2020[23]. - The diluted earnings per share for 2021 was also ¥0.50, reflecting the same decline as the basic earnings per share[24]. Dividend Distribution - The company plans to distribute a cash dividend of 3.2 CNY per 10 shares, totaling approximately 450.77 million CNY, which accounts for 65.32% of the net profit attributable to shareholders[6]. - The total cash dividend for the current year is projected to be 318,069,118.41 CNY, making up 30.70% of the net profit attributable to shareholders[129]. - The company implemented a cash dividend policy, distributing 2.1 CNY per 10 shares in 2019, totaling 291,179,501.13 CNY, which accounted for 28.10% of the net profit attributable to shareholders[128]. - In 2020, the company increased the cash dividend to 3.5 CNY per 10 shares, amounting to 485,299,168.55 CNY, representing 50.76% of the net profit attributable to shareholders[129]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The board of directors has confirmed that all members attended the board meeting, ensuring accountability for the report's accuracy[4]. - There are no significant risks that would prevent the board from ensuring the report's authenticity and completeness[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The internal control audit report issued by the accounting firm provided a standard unqualified opinion[137]. - The company reported no significant deficiencies in internal control during the reporting period[137]. Strategic Acquisitions and Investments - The company plans to acquire 84% of Hangzhou Mingzhou Brain Rehabilitation Hospital and 85% of Nanchang Mingzhou Rehabilitation Hospital, indicating a strategic expansion in the healthcare sector[99]. - The company is actively expanding its market presence through strategic acquisitions of rehabilitation hospitals[168]. - The company approved the acquisition of 84% equity of Hangzhou Mingzhou Brain Rehabilitation Hospital through various partnerships[168]. - The company intends to use RMB 32 million of raised funds to acquire 100% equity of Nanjing Mingzhou Rehabilitation Hospital[168]. - The company plans to use RMB 40.32 million of raised funds to acquire 70% and 15% equity of Nanjing Mingzhou Rehabilitation Hospital[168]. Market and Operational Risks - The company has outlined potential risks in its future development in the management discussion and analysis section[8]. - The company is exposed to operational risks associated with new hospital investments, which have long payback periods and potential integration challenges post-acquisition[89]. - The competitive landscape in the medical services industry is intense, with significant risks related to market competition and regulatory changes[88]. - The company is actively monitoring the impact of the ongoing COVID-19 pandemic on its business operations and expansion plans[89]. Research and Development - Research and development expenses amounted to approximately ¥294 million, a decrease of 5.99% from the previous year[50]. - The company employed 743 R&D personnel, accounting for 11.30% of the total workforce[60]. - The company is focusing on rehabilitation medical services as a key growth area, integrating ICU and rehabilitation services to improve patient recovery outcomes[47]. Environmental and Social Responsibility - The company has maintained compliance with environmental standards, with actual emissions of COD at 9.126 tons per year, below the regulatory limit[139]. - The company actively promotes energy-saving and environmental protection measures in its production processes[149]. - The company has been involved in various public welfare activities, providing support to disadvantaged groups during traditional festivals[152]. - During the pandemic, the company’s hospitals executed 24-hour nucleic acid testing, ensuring continuous service without breaks[153]. Governance and Management - The company has a structured compensation mechanism for senior management, consisting of a base salary and performance-based pay, evaluated by a compensation committee[127]. - The company has established specialized committees within the board, including an Audit Committee and a Strategic Committee, to enhance decision-making processes[115]. - The company has maintained a high level of attendance at board meetings, with no director missing more than two meetings, reflecting strong engagement from the board[114]. - The company has undergone significant management changes, including the resignation of the previous president, Duan Liang, due to work changes[110].

[Key Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%20%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) The company's revenue and net profit declined in Q1-Q3 2021, accompanied by a significant drop in operating cash flow [Core Financial Indicators](index=1&type=section&id=1.1%20%E6%A0%B8%E5%BF%83%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Revenue and net profit declined in Q1-Q3 2021, with operating cash flow turning negative due to inventory buildup 2021 Q1-Q3 Key Financial Indicators | Indicator | YTD Q3 2021 | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 5,103,632,532.88 CNY | -7.05% | | Net Profit Attributable to Shareholders | 667,219,123.50 CNY | -8.67% | | Net Profit Attributable to Shareholders (Non-recurring Items Excluded) | 593,084,160.59 CNY | 0.32% | | Net Cash Flow from Operating Activities | -474,955,452.90 CNY | -437.72% | | Basic Earnings Per Share (CNY/Share) | 0.48 CNY | -8.90% | | Weighted Average Return on Equity | 7.51% | Decreased by 1.43 p.p. | | Total Assets (at Period-End) | 13,827,924,657.06 CNY | 0.96% (vs. Year-End 2020) | | Equity Attributable to Shareholders (at Period-End) | 8,672,402,954.51 CNY | 0.60% (vs. Year-End 2020) | - Net cash flow from operating activities **decreased sharply by 437.72%** YoY, primarily due to increased payments for goods to build up inventory amid supply chain tensions and rising prices for chips and commodities[8](index=8&type=chunk) 2021 Q1-Q3 Non-Recurring Profit and Loss Items | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -2,208,922.30 | | Government Grants Included in Current Profit/Loss | 30,427,550.15 | | Fair Value Change Gains/Losses on Trading Financial Assets/Liabilities | 59,889,549.18 | | Other Net Non-operating Income and Expenses | 7,002,576.21 | | **Total** | **74,134,962.92** | [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%20%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) The report details the company's shareholder structure, including the total number of shareholders and top ten holdings [Shareholder Structure](index=3&type=section&id=2.1%20%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) The company had 27,355 common shareholders, with AUX Group as the controlling shareholder and related parties among top holders - As of the end of the reporting period, the total number of common shareholders was **27,355**[9](index=9&type=chunk) Top Ten Shareholders | Shareholder Name | Number of Shares | Shareholding Ratio (%) | | :--- | :--- | :--- | | AUX Group Co., Ltd. | 457,719,653 | 33.01 | | Zheng Jianjiang | 207,306,730 | 14.95 | | Zheng Jiang | 66,395,000 | 4.79 | | He Xiwan | 35,420,000 | 2.55 | | Lu Anjun | 31,760,250 | 2.29 | | Xu Xingen | 27,700,000 | 2.00 | | Golden Eagle Fund - SPD Bank - Golden Eagle Suitong Private Placement No. 136 | 21,088,410 | 1.52 | | Zhu Qijun | 19,936,943 | 1.44 | | Shanghai Regan Asset - Regan CTA Composite Strategy No. 3 | 18,000,000 | 1.30 | | Shanghai Regan Asset - Regan Tianbao All-Weather No. 3 | 15,000,000 | 1.08 | - The controlling shareholder is AUX Group Co., Ltd., and the actual controller is Zheng Jianjiang; Zheng Jiang is the brother of Zheng Jianjiang, and He Xiwan is the brother of Zheng Jianjiang's spouse, He Yiju[11](index=11&type=chunk) [Other Significant Matters](index=5&type=section&id=%E4%B8%89%E3%80%81%20%E5%85%B6%E4%BB%96%E6%8F%90%E9%86%92%E4%BA%8B%E9%A1%B9) This section confirms the absence of other significant operational matters requiring special investor attention during the period [Important Information Reminder](index=5&type=section&id=3.1%20%E9%87%8D%E8%A6%81%E4%BF%A1%E6%81%AF%E6%8F%90%E9%86%92) No other significant operational information requires special investor attention during this reporting period - The company has no other significant information regarding its operations that requires special investor attention during this reporting period[12](index=12&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=%E5%9B%9B%E3%80%81%20%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the consolidated balance sheet, income statement, and cash flow statement for Q1-Q3 2021 [Consolidated Balance Sheet](index=5&type=section&id=4.1%20%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Total assets grew slightly to CNY 13.83 billion, driven by increases in receivables and inventories, with a 36.97% debt-to-asset ratio Key Balance Sheet Items (Unit: CNY) | Item | Sep 30, 2021 | Dec 31, 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 13,827,924,657.06 | 13,696,278,189.50 | 0.96% | | Total Liabilities | 5,111,723,528.86 | 4,911,338,256.40 | 4.08% | | Equity Attributable to Parent Company | 8,672,402,954.51 | 8,620,717,871.96 | 0.60% | Key Asset Item Changes (Unit: CNY) | Item | Sep 30, 2021 | Dec 31, 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 2,230,336,320.89 | 2,561,665,416.04 | -12.93% | | Accounts Receivable | 2,416,254,015.95 | 1,805,406,435.47 | 33.84% | | Inventories | 1,065,462,238.39 | 640,114,379.32 | 66.45% | | Non-current Assets Due within One Year | 909,434,436.09 | 1,436,415,512.66 | -36.69% | [Consolidated Income Statement](index=7&type=section&id=4.2%20%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Revenue and net profit for Q1-Q3 2021 decreased by 7.05% and 8.67% respectively, with profits supported by cost control and investment gains Core Income Statement Data (2021 Q1-Q3) | Item | Amount (CNY) | YoY Change | | :--- | :--- | :--- | | Total Operating Revenue | 5,103,632,532.88 | -7.05% | | Total Operating Costs | 4,550,349,761.95 | -4.90% | | Investment Income | 154,856,127.37 | 299.38% | | Gain from Fair Value Changes | 32,296,749.31 | -84.53% | | Total Profit | 792,623,427.10 | -9.05% | | Net Profit | 672,924,192.22 | -8.34% | | Net Profit Attributable to Parent Company Shareholders | 667,219,123.50 | -8.67% | [Consolidated Cash Flow Statement](index=10&type=section&id=4.3%20%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Operating cash flow turned negative to -CNY 475 million due to increased payments, while investing activities generated a net inflow Key Cash Flow Data (2021 Q1-Q3) | Item | Amount (CNY) | Same Period Last Year (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -474,955,452.90 | 140,637,230.15 | | Net Cash Flow from Investing Activities | 659,990,344.91 | -121,593,297.15 | | Net Cash Flow from Financing Activities | -486,625,357.59 | -862,116,777.78 | | Net Increase in Cash and Cash Equivalents | -309,422,917.03 | -850,492,625.43 | [Impact of Adopting New Lease Standard](index=12&type=section&id=4.4%20%E6%96%B0%E7%A7%9F%E8%B5%81%E5%87%86%E5%88%99%E6%89%A7%E8%A1%8C%E5%BD%B1%E5%93%8D) The company adopted the new lease standard on Jan 1, 2021, recognizing right-of-use assets and lease liabilities on the balance sheet - The company adopted the new lease standard (ASBE No. 21 - Leases) issued by the Ministry of Finance in 2018, effective January 1, 2021, and adjusted relevant financial statement items accordingly[28](index=28&type=chunk) Key Adjustments to Opening Balance Sheet from First-time Adoption | Adjusted Item | Adjustment Amount (CNY) | | :--- | :--- | | **Assets** | | | Right-of-use Assets | +85,806,950.78 | | Deferred Tax Assets | +2,570,344.32 | | Prepayments | -494,400.00 | | **Liabilities** | | | Lease Liabilities | +101,037,242.25 | | Other Payables | -4,144,847.54 | | **Equity** | | | Retained Earnings | -7,910,884.64 |